ADVOCACY
STATE ADVOCACY
MOS President Testifies Against Missouri HJR 117
Additionally, the bill would place work reporting requirements on those in the expansion population, creating bureaucratic barriers and additional access challenges for patients with cancer, potentially causing Medicare patients to lose their healthcare.
MOS believes expansion will go a long way in providing greater access to cancer screening, diagnosis, and treatment for Missourians. Last month, MOS and the Association for Clinical Oncology wrote a letter to Chairman Cody Smith and members of the House Budget Committee expressing concern with HJR 117 and the seriously negative consequences it could have on patients with cancer.
MOS strongly opposes HJR 117 and believes that no individual diagnosed with cancer should be without health insurance that guarantees access to high-quality cancer care.
FEDERAL ADVOCACY
MOS Issues Protest Letter to Payers on IV Iron Therapy Policy
July 13, 2022
The Missouri Oncology Society (MOS) issued a letter protesting payer policies that direct providers to use only one type of intravenous iron therapy.
The policy’s economic considerations seem to focus on product acquisition costs only and fail to take into account the multitude of issues that increase costs to the patient and provider.
MOS Joins 400+ Organizations in Support of MCED Legislation
May 5, 2022
The Missouri Oncology Society (MOS) joined more than 400 organization from all 50 states to urge Congress to pass the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act (H.R.1946/S.1873) this year. This legislation would create a pathway for MCED tests to be covered by the Medicare program following approval by the Food and Drug Administration (FDA).
Read the Letter
Copyright © Missouri Oncology Society. All rights reserved.
Privacy Policy